DE19975039I2 - Behandlung von Obesitas - Google Patents

Behandlung von Obesitas

Info

Publication number
DE19975039I2
DE19975039I2 DE1999175039 DE19975039C DE19975039I2 DE 19975039 I2 DE19975039 I2 DE 19975039I2 DE 1999175039 DE1999175039 DE 1999175039 DE 19975039 C DE19975039 C DE 19975039C DE 19975039 I2 DE19975039 I2 DE 19975039I2
Authority
DE
Germany
Prior art keywords
obesity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE1999175039
Other languages
English (en)
Inventor
Monte Scheinbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23060006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE19975039(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Knoll GmbH filed Critical Knoll GmbH
Application granted granted Critical
Publication of DE19975039I2 publication Critical patent/DE19975039I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
DE1999175039 1988-11-29 1989-11-21 Behandlung von Obesitas Active DE19975039I2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27724088A 1988-11-29 1988-11-29

Publications (1)

Publication Number Publication Date
DE19975039I2 true DE19975039I2 (de) 2000-03-30

Family

ID=23060006

Family Applications (2)

Application Number Title Priority Date Filing Date
DE89912801T Expired - Lifetime DE68909219T2 (de) 1988-11-29 1989-11-21 Behandlung von obesitas.
DE1999175039 Active DE19975039I2 (de) 1988-11-29 1989-11-21 Behandlung von Obesitas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE89912801T Expired - Lifetime DE68909219T2 (de) 1988-11-29 1989-11-21 Behandlung von obesitas.

Country Status (16)

Country Link
US (1) US5436272A (de)
EP (1) EP0397831B1 (de)
JP (1) JPH06102622B2 (de)
KR (1) KR0164435B1 (de)
AU (1) AU633529B2 (de)
CA (1) CA2003524C (de)
DE (2) DE68909219T2 (de)
DK (1) DK175587B1 (de)
HK (1) HK1006002A1 (de)
IE (1) IE61928B1 (de)
IL (1) IL92406A (de)
LU (1) LU90866I2 (de)
NL (1) NL300066I2 (de)
PH (1) PH26677A (de)
WO (1) WO1990006110A1 (de)
ZA (1) ZA899058B (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
CA2138998A1 (en) * 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
AU721924B2 (en) * 1992-06-23 2000-07-20 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
WO2000056321A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
EP1169027A4 (de) * 1999-03-19 2004-10-20 Abbott Gmbh & Co Kg Arthrosebehandlung
EP1178789B1 (de) * 1999-03-19 2008-07-16 Abbott GmbH & Co. KG Methoden zur behandlung der essstörungen
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6376551B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
WO2000056313A1 (en) * 1999-03-19 2000-09-28 Knoll Gmbh Method of controlling weight gain associated with therapeutic drugs
AU3894600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating sexual dysfunction
MXPA01009462A (es) * 1999-03-19 2004-03-19 Knoll Gmbh Tratamiento de calculos biliares.
WO2000056308A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention of cardiovascular disease
AU3895400A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Control of metabolism
TR200102694T2 (tr) * 1999-03-19 2002-04-22 Knoll Gmbh Hamilelik sonrası kilo kaybı.
PL359467A1 (en) * 1999-03-19 2004-08-23 Knoll Gmbh Method of treating sleep apnoea
US6403650B1 (en) 1999-03-19 2002-06-11 Knoll Pharmaceutical Company Treatment of pulmonary hypertension
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9926251D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Pharmaceutical formulation
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
FR2814678B1 (fr) † 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
ATE486842T1 (de) * 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
KR100830002B1 (ko) 2005-01-06 2008-05-15 씨제이제일제당 (주) 시부트라민의 무기산염
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
EP1938811A4 (de) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd Medizinische zusammensetzung zur behandlung von bulimie und mit bulimie einhergehenden depressionen
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
BRPI0618354B8 (pt) 2005-11-10 2021-05-25 Banyu Pharma Co Ltd composto e seu uso, composição farmacêutica, preventivo ou remédio
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
EA200900392A1 (ru) 2006-09-07 2010-06-30 Никомед Гмбх Комбинированное лечение сахарного диабета
RU2462451C2 (ru) 2006-09-15 2012-09-27 Ривайва Фармасьютикалс, Инк. Способ получения, способы применения и композиции циклоалкилметиламинов
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
KR20090127904A (ko) * 2007-04-09 2009-12-14 싸이도우스 엘엘씨. 스타틴과 항비만제의 복합물
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PL2152663T3 (pl) 2007-06-04 2014-09-30 Ben Gurion Univ Of The Negev Research And Development Authority Związki triarylowe oraz kompozycje zawierające te związki
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
EP2321341B1 (de) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
EP2319841A1 (de) 2008-07-30 2011-05-11 Msd K.K. (5-gliedriges)-(5-gliedriges) oder (5-gliedriges)-(6-gliedriges) kondensiertes ringcycloalkylaminderivat
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US20100311710A1 (en) * 2008-12-06 2010-12-09 Auspex Pharmaceuticals, Inc. Cyclobutanemethanamine inhibitors of monoamine reuptake
EP2379547A1 (de) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidinderivate und verfahren zu deren anwendung
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2538784B1 (de) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazolderivate als antidiabetika
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR20150075120A (ko) 2011-02-25 2015-07-02 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
EP2970119B1 (de) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Neuartige indolderivate als antidiabetika
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6657101B2 (ja) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ 糖尿病及びそれから生じる疾患合併症の治療のための化合物
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
CN109952292A (zh) 2016-10-14 2019-06-28 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
EP3551176A4 (de) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetische heterocyclische verbindungen
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
JP2022507805A (ja) 2018-11-20 2022-01-18 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α－アミノ－β－カルボキシムコン酸セミアルデヒドデカルボキシラーゼ阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment

Also Published As

Publication number Publication date
NL300066I2 (nl) 2002-06-03
LU90866I2 (fr) 2002-02-18
KR900701261A (ko) 1990-12-01
IE61928B1 (en) 1994-11-30
DE68909219D1 (de) 1993-10-21
AU4620789A (en) 1990-06-26
EP0397831A1 (de) 1990-11-22
EP0397831B1 (de) 1993-09-15
JPH02503682A (ja) 1990-11-01
JPH06102622B2 (ja) 1994-12-14
WO1990006110A1 (en) 1990-06-14
US5436272A (en) 1995-07-25
IL92406A (en) 1995-07-31
DK175587B1 (da) 2004-12-13
DK177690A (da) 1990-09-13
CA2003524C (en) 1999-10-19
ZA899058B (en) 1990-08-29
DK177690D0 (da) 1990-07-26
KR0164435B1 (ko) 1999-01-15
IE893690L (en) 1990-05-29
DE68909219T2 (de) 1994-01-13
CA2003524A1 (en) 1990-05-29
HK1006002A1 (en) 1999-02-05
AU633529B2 (en) 1993-02-04
NL300066I1 (nl) 2001-12-01
PH26677A (en) 1992-09-15

Similar Documents

Publication Publication Date Title
DE19975039I2 (de) Behandlung von Obesitas
DE68920775T2 (de) Behandlung von faserigen Materialien.
ATE131068T1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE69215345D1 (de) Behandlung von Synthesegas
ATA209789A (de) Behandlung von zementpulver
DE69019488T2 (de) Behandlung von Geflügel.
DE68907423T2 (de) Behandlung der Akne.
DE69018043D1 (de) Behandlung von Geflügel.
DE69224173T2 (de) Behandlung von lignocellulosischen Materialien
DE3777861D1 (de) Behandlung von gasen.
DE3680881D1 (de) Behandlung von hologrammen.
DE68923219T2 (de) Behandlung von Abfällen.
DE69132054T2 (de) Behandlung von windelausschlag
DE69325141D1 (de) Behandlung von lignozellulosehaltigen Materialien
DE69306831T2 (de) Behandlung von Flüssigkeiten
ATE74537T1 (de) Behandlung von gebrauchten antimonhalidkatalysatoren.
ATE94385T1 (de) Behandlung von obesitas.
DE69318644T2 (de) Behandlung von Flüssigkeiten
DE3667518D1 (de) Behandlung von archivmaterial.
ATE101795T1 (de) Behandlung von osteoporosis.
DE3673072D1 (de) Behandlung von lignocellulosematerialien.
DE68905465D1 (de) Behandlung von rhodium-katalysatoren.
ATE48669T1 (de) Behandlung von archivmaterial.
ATE88116T1 (de) Behandlung von metallbrammen.
ATE92796T1 (de) Behandlung von metallbrammen.